Ver­sant and Ab­Cellera go deep­er on an­ti­bod­ies, push­ing for­ward a trio of stealth com­pa­nies

Ver­sant is putting the bow on a new deal with an­ti­body de­vel­op­er Ab­Cellera on Wednes­day.

The two com­pa­nies aren’t say­ing much, de­clin­ing to dis­close fi­nan­cial de­tails or the tar­gets they’ll be work­ing to­ward. What will hap­pen, Ver­sant says, is that the firm’s still-in-stealth port­fo­lio com­pa­nies will de­vel­op the an­ti­bod­ies us­ing Ab­Cellera in­sight, with the lat­ter el­i­gi­ble for down­stream mile­stones and re­search pay­ments.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER